期刊文献+

肠道微生态对肿瘤免疫治疗的影响 被引量:2

Effects of intestinal microbiota on cancer immunotherapy
下载PDF
导出
摘要 近年来,研究表明肠道微生态对肿瘤免疫治疗有重要的影响,肠道微生态与各类免疫检查点抑制剂如抗细胞毒性T淋巴细胞相关抗原4抗体、抗程序性细胞死亡蛋白1抗体以及抗程序性细胞死亡蛋白配体1抗体的疗效密切相关。本文回顾分析了相关基础及临床研究的最新进展,发现诸如Akkermansia muciniphila、双歧杆菌等重要有益菌可提升肿瘤免疫治疗的效果并作为生物标志物。因此,推测多样化的肠道微生态有利于维持机体内环境稳定,肠道微生态的合理调控可提高肿瘤免疫治疗效果,并减轻不良反应。 Recent studies indicate that intestinal microbiota plays an important role in cancer immunotherapy.Intestinal microbiota is closely related to the treatment effect of immune checkpoint inhibitors targeting cytotoxic T lymphocyte associated antigen 4,programmed cell death protein 1 and programmed cell death protein 1 ligand.Our study analyzes recent progress of related basic and clinical studies and finds that several bacteria such as Akkermansia muciniphila and Bifidobacterium can improve cancer immunotherapy efficacy and may act as a biomarker.Therefore,we conclude that diversified intestinal microbiota can maintain the stability of the internal environment,and equitable regulation of intestinal microbiota can improve the efficacy of cancer immunotherapy and reduce adverse reactions.
作者 金怡 郑怡 张航瑜 赵鹏 涂晓璇 吴伟 刘璐璐 方维佳 JIN Yi;ZHENG Yi;ZHANG Hang-yu;ZHAO Peng;TU Xiao-xuan;WU Wei;LIU Lu-lu;FANG Wei-jia(Department of Traditional Chinese Medicine and Western Medicine,Peoples's Hospital of Sanmen County,Taizhou 317100,China)
出处 《传染病信息》 2018年第4期372-376,共5页 Infectious Disease Information
基金 浙江省重大科技专项(2017C03028)
关键词 肠道微生态 免疫 免疫检查点抑制剂 肿瘤免疫治疗 intestinal microbiota immune immune checkpoint inhibitors cancer immunotherapy
  • 相关文献

参考文献1

二级参考文献48

  • 1Venook AP, Papandreou C, Furuse J, et al. The incidence andepidemiology of hepatocellular carcinoma: a global and regionalperspective [J] . Oncologist, 2010, 15(Suppl 4):S5-S13.
  • 2Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinomaepidemiology [J] . Best Pract Res Clin Gastroenterol, 2014,28(5):753-770.
  • 3Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenibin patients in the Asia-Pacific region with advanced hepatocellularcarcinoma: a phase ID randomised, double-blind, placebo-controlledtrial [J] . Lancet Oncol, 2009, 10(1):25-34.
  • 4Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advancedhepatocellular carcinoma [j] . N Engl J Med, 2008,359(4):378-390.
  • 5Mizukoshi E, Yamashita T, Arai K, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequencyablation of hepatocellular carcinoma [J] . Hepatology, 2013,57(4):1448-1457.
  • 6Ali MY, Grimm CF, Ritter M, et al. Activation of dendritic cells bylocal ablation of hepatocellular carcinoma [j] . J Hepatol, 2005,43(5):817-822.
  • 7Bricard G, Bouzourene H, Martinet O, et al. Naturally acquiredMAGE-A10- and SSX-2-specific CD8+ T cell responses inpatients with hepatocellular carcinoma [J] . J Immunol, 2005,174(3):1709-1716.
  • 8Butterfield LH, Koh A, Meng W, et al. Generation of human T-cellresponses to an HLA-A2.1 -restricted peptide epitope derived fromalpha-fetoprotein [J] . Cancer Res, 1999, 59(13):3134-3142.
  • 9Cicinnati VR, Zhang X, Yu Z, et al. Increased frequencies ofCD8+ T lymphocytes recognizing wild-type p53-derived epitopesin peripheral blood correlate with presence of epitope loss tumorvariants in patients with hepatocellular carcinoma [J] . Int JCancer, 2006, 119(12):2851-2860.
  • 10Komori H, Nakatsura T, Senju S, et al. Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma [J] . ClinCancer Res, 2006, 12(9):2689-2697.

共引文献2

同被引文献29

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部